NorChip

PreTect, formerly known as NorChip, is a Norwegian biotechnology company specializing in molecular diagnostics for the early detection of cancer. The company is a pioneer in the development of mRNA-based assays, specifically targeting the E6/E7 oncogenes of high-risk Human Papillomavirus (HPV). By utilizing Nucleic Acid Sequence Based Amplification (NASBA) technology, PreTect's products identify active viral infections that are likely to lead to malignancy, offering higher specificity than traditional DNA-based tests. Their flagship products, including PreTect HPV-ProExpress and PreTect SEE, are designed to improve patient triage and reduce over-treatment in cervical cancer screening programs. The company continues to innovate in the field of molecular pathology from its headquarters in Norway.